Aurinia Pharmaceuticals (AUPH) AI Stock Analysis

• Market Cap: $1.23B
• Dividend Yield: N/A
• Average Volume (3M): 1.80M
• Price to Earnings (P/E): 32.8
• Beta (1Y): 0.91
• Revenue Growth: 29.20%
• EPS Growth: N/A
• Country: US
• Employees: 130
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 135,104,310
• 10 Day Avg. Volume: 2,103,234
• 30 Day Avg. Volume: 1,800,622
• PEG Ratio: 0.05
• Price to Book (P/B): 3.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 18.80
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 1.35
• Enterprise Value/Gross Profit: 5.62
• Enterprise Value/Ebitda: 21.03
• 1Y Price Target: $9.75
• Price Target Upside: 7.50% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 73 Outperform
• Price Target: $9.50 ▲(4.74%Upside)

Aurinia Pharmaceuticals has a solid overall stock score, driven by strong financial performance and positive earnings call highlights. However, the high valuation and mixed technical signals, along with potential risks from patent litigation and market competition, moderate the score.

Positive Factors

Financial Performance

Aurinia reported 1Q-2025 results beating estimates.

Product Revenue

Lupkynis product revenue came in ahead of estimates, increasing 25% year-over-year.

Negative Factors

Sales Guidance

Sales guidance for FY25 is within expectations but below consensus.

Strategic Position

Disappointment that Aurinia will remain standalone, as more value could have been created with strategic synergies within a more established commercial organization.

Aurinia Pharmaceuticals Business Overview & Revenue Model

Company Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

How the Company Makes Money

Aurinia Pharmaceuticals generates revenue primarily through the sales of its FDA-approved drug, Lupkynis. The company markets this drug mainly in North America, and it is designed to treat patients with active lupus nephritis. Aurinia also seeks revenue through partnerships and collaborations with other pharmaceutical companies to expand the reach and application of its products. Additionally, the company may receive milestone payments and royalties as part of licensing agreements with other entities involved in the development and commercialization of its drug. These partnerships and collaborations play a significant role in the company's financial growth and market expansion.

Aurinia Pharmaceuticals Financial Statement Overview

Summary

Aurinia Pharmaceuticals exhibits strong financial performance, with substantial revenue and profitability growth, a stable balance sheet with low leverage, and healthy cash flows. The improvement in Gross Profit Margin and Net Profit Margin, along with positive EBIT and EBITDA margins, indicates effective operational management.

Income Statement

Aurinia Pharmaceuticals has shown impressive revenue growth, with Total Revenue increasing from $134.03 million in 2022 to $247.30 million TTM (Trailing-Twelve-Months) in 2025, reflecting a robust growth trajectory. The Gross Profit Margin and Net Profit Margin have significantly improved, indicating better operational efficiency and profitability. EBIT and EBITDA margins have turned positive in the TTM period, showcasing a strong recovery from past losses.

Balance Sheet

The balance sheet is solid with a Debt-to-Equity Ratio well under 1, indicating low leverage. The company's Return on Equity has improved due to positive Net Income, enhancing shareholder value. However, the Equity Ratio has decreased slightly, reflecting a more balanced asset and liability management.

Cash Flow

The company exhibits a positive trend in Free Cash Flow with significant growth, suggesting improved financial health. The Operating Cash Flow to Net Income Ratio shows strong cash generation relative to net earnings. The Free Cash Flow to Net Income Ratio also indicates that cash flows are robust in relation to profitability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	235.13M	175.51M	134.03M	45.60M	50.12M
Gross Profit	206.88M	161.37M	128.37M	44.51M	-209.00K
EBITDA	31.73M	-63.05M	-103.65M	-177.44M	-102.92M
Net Income	5.75M	-78.02M	-108.18M	-180.97M	-102.68M
Balance Sheet
Total Assets	550.64M	548.06M	470.86M	543.37M	463.66M
Cash, Cash Equivalents and Short-Term Investments	358.48M	350.49M	389.39M	466.08M	398.33M
Total Debt	79.37M	97.61M	8.09M	8.74M	8.41M
Total Liabilities	173.17M	170.11M	65.42M	64.28M	55.91M
Stockholders Equity	377.48M	377.95M	405.44M	479.09M	407.75M
Cash Flow
Free Cash Flow	44.11M	-34.18M	-79.82M	-159.19M	-77.20M
Operating Cash Flow	44.39M	-33.46M	-79.53M	-157.69M	-69.86M
Investing Cash Flow	39.26M	-6.71M	-60.63M	-103.87M	-158.19M
Financing Cash Flow	-49.09M	-5.13M	2.43M	221.11M	194.38M

Aurinia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUPH, the sentiment is Positive. The current price of 9.07 is above the 20-day moving average (MA) of 8.44, above the 50-day MA of 8.21, and above the 200-day MA of 8.13, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 62.65 is Neutral, neither overbought nor oversold. The STOCH value of 69.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUPH.

Aurinia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	73 Outperform	$1.23B	32.84	11.23%	―	29.20%	―
ARDX	64 Neutral	$1.05B	―	-36.26%	―	127.33%	21.31%
LQDA	60 Neutral	$1.52B	―	-188.03%	―	-11.42%	0.26%
CLDX	52 Neutral	$1.58B	―	-23.20%	―	24.49%	5.14%
Sector *	52 Neutral	$7.62B	0.05	-63.03%	2.44%	16.33%	0.31%
OCUL	51 Neutral	$1.84B	―	-57.19%	―	-0.33%	-3.59%
IOVA	49 Neutral	$1.33B	―	-51.85%	―	11070.12%	32.07%

Aurinia Pharmaceuticals Corporate Events

Aurinia Pharmaceuticals Approves New Equity Incentive Plan

At the annual general meeting held on May 15, 2025, Aurinia Pharmaceuticals‘ shareholders approved an amended Equity Incentive Plan and revised Bylaws allowing shareholders to set the number of directors. The meeting also resulted in the election of several board members and the approval of PricewaterhouseCoopers LLP as the company’s independent accounting firm. These changes are expected to enhance corporate governance and align executive compensation with shareholder interests.

The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.